Literature DB >> 17118357

Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Mark Nagata1, Teri Wong, David Clements, George Hui.   

Abstract

Hyperimmunization with Plasmodium falciparum MSP1-42 could induce antibodies that have little or no parasite growth inhibitory activities. These antisera had no blocking activities as determined by their ability to interfere with the in vitro activities of growth inhibitory anti-MSP1-42 sera. Equally important, they enhanced the potency of growth inhibitory anti-MSP1-42 sera.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17118357      PMCID： PMC1857355          DOI： 10.1016/j.exppara.2006.10.005

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN： 0014-4894            Impact factor:   2.011


  42 in total

1.  Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge.

Authors:  Peter Vukovic; Ke Chen; Xue Qin Liu; Michael Foley; Andrew Boyd; David Kaslow; Michael F Good
Journal:  Vaccine       Date:  2002-06-21       Impact factor: 3.641

2.  Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

Authors:  Jiraprapa Wipasa; Huji Xu; Morris Makobongo; Michelle Gatton; Anthony Stowers; Michael F Good
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

3.  A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

Authors:  Anthony W Stowers; Li-how Chen Lh; Yanling Zhang; Michael C Kennedy; Lanling Zou; Lynn Lambert; Timothy J Rice; David C Kaslow; Allan Saul; Carole A Long; Harry Meade; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Authors:  A W Stowers; V Cioce; R L Shimp; M Lawson; G Hui; O Muratova; D C Kaslow; R Robinson; C A Long; L H Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.

Authors:  Sanjay Singh; Kazutoyo Miura; Hong Zhou; Olga Muratova; Brian Keegan; Aaron Miles; Laura B Martin; Allan J Saul; Louis H Miller; Carole A Long
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 6.  Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.

Authors:  A A Holder; J A Guevara Patiño; C Uthaipibull; S E Syed; I T Ling; T Scott-Finnigan; M J Blackman
Journal:  Parassitologia       Date:  1999-09

7.  Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.

Authors:  C Uthaipibull; B Aufiero; S E Syed; B Hansen; J A Guevara Patiño; E Angov; I T Ling; K Fegeding; W D Morgan; C Ockenhouse; B Birdsall; J Feeney; J A Lyon; A A Holder
Journal:  J Mol Biol       Date:  2001-04-13       Impact factor: 5.469

8.  Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

Authors:  R A O'Donnell; T F de Koning-Ward; R A Burt; M Bockarie; J C Reeder; A F Cowman; B S Crabb
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

9.  A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies.

Authors:  Tania F de Koning-Ward; Rebecca A O'Donnell; Damien R Drew; Russell Thomson; Terence P Speed; Brendan S Crabb
Journal:  J Exp Med       Date:  2003-09-08       Impact factor: 14.307

10.  The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.

Authors:  Roseangela I Nwuba; Olugbemiro Sodeinde; Chiaka I Anumudu; Yusuf O Omosun; Alexander B Odaibo; Anthony A Holder; Mark Nwagwu
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441
View more
  1 in total

1.  T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines.

Authors:  Kae M Pusic; Caryn N Hashimoto; Axel Lehrer; Charmaine Aniya; David E Clements; George S Hui
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.